SCYNEXIS, Inc. (0L49.L)

2.7650 +0.4900 (+21.54%) At close: 05:30PM BST

SCYNEXIS, Inc.

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485
https://www.scynexis.com

Sector(s): 
Industry: 
Full-time employees: 56

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Marco Taglietti M.D.	CEO, Pres & Director	905.92k	N/A	1960
Mr. David Gonzalez Angulo	Chief Medical Officer	678.42k	N/A	1965
Ms. Christine R. Coyne M.B.A.	Chief Commercial Officer	541.84k	N/A	1969
Mr. Lawrence R. Hoffman CPA, Esq.	Interim Chief Financial Officer	N/A	N/A	1955
Mr. Scott Sukenick J.D.	Gen. Counsel & Corp. Sec.	N/A	N/A	1978
Debbie Etchison	Exec. Director of Communications	N/A	N/A	N/A
Dr. Rajeshwar Motheram	Sr. VP of Pharmaceutical Devel. & Supply Chain	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Corporate governance

SCYNEXIS, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.